Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.France-based ophthalmic company Novagali Pharma has announced the positive results of its first set of data pertaining to Nova21027, its BAK-free latanoprost formulation for glaucoma.
Subscribe to our email newsletter
The experimental work has been performed in collaboration with Christophe Baudouin from the Quinze-Vingts National Ophthalmology Hospital and Science Faculty of Paris V, France.
According to the company, acute toxicological studies have confirmed the ocular surface toxicity of anti-glaucomatous eye drops containing benzalkonimum chloride while Novagali’s BAK-free cationic emulsion of latanoprost was well tolerated and did not induce any ocular surface damages upon stress conditions. The company will report further data in May 2009.
Jerome Martinez, CEO of Novagali, said: “It is now admitted that BAK has a deleterious effect especially in ocular surface diseases and after long-term or combination therapies. This BAK-free formulation of latanoprost demonstrated both efficacy and safety in various preclinical models.”